Why some US patients research cell therapy abroad — and what to verify
Patients may look abroad because access, eligibility, cost and waiting time differ. Travel does not make an unapproved product authorised, proven or safer.
Some US patients research care abroad when they cannot find an authorised treatment or suitable clinical trial at home, or when they receive a lower overseas quotation. These are understandable reasons to compare options, but they do not answer the central questions: what exact product is being offered, under which legal route, for which indication, and with what evidence and follow-up?
The US Food and Drug Administration states that the only FDA-approved stem-cell products are blood-forming cells derived from umbilical-cord blood for disorders affecting blood formation. It also warns that marketed stem-cell, stromal vascular fraction, amniotic, Wharton's jelly and exosome products generally require FDA approval or use under FDA oversight in a clinical trial. Registration of a company or listing of a study on ClinicalTrials.gov does not itself mean that a product is approved or lawfully marketed.
European access must be verified independently. EU advanced therapy medicinal products generally require marketing authorisation, an authorised clinical trial, or a national-authority exemption under the conditions that apply to a hospital and an individual patient. “Experimental,” “autologous,” “minimally manipulated,” a tissue-establishment registration or a generic GMP claim is not a substitute for the exact regulatory reference.
Before travelling, request the protocol, product identity, manufacturer and site, regulator reference, consent form, known risks, alternatives, eligibility and exclusion criteria, adverse-event process and follow-up plan. Confirm who is clinically responsible after you return, how records will be transferred and what happens if travel must be extended. Check travel insurance in writing; standard policies may exclude planned treatment and complications arising from it.
Seek an independent specialist opinion and compare registered trials before paying a deposit. FDA's regenerative-medicine patient information and the EMA/HMA warning on unregulated ATMPs provide regulator-level checks that apply before any country or price comparison.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.